LungLife AI, INC Notice of Results (8502Y)
September 09 2022 - 2:01AM
UK Regulatory
TIDMLLAI
RNS Number : 8502Y
LungLife AI, INC
09 September 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
Notice of Results
Investor Presentation
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, will announce its interim results for
the six months ended 30 June 2022 on Monday 26 September 2022.
Investor presentation
Paul Pagano, Chief Executive Officer, and David Anderson, Chief
Financial Officer, will be hosting a live online presentation
relating to the full year results via the Investor Meet Company
platform at 4.30pm (GMT) on Monday 26 September 2022. The
presentation is open to all existing and potential
shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation here:
https://www.investormeetcompany.com/lunglife-ai-inc/register-investor
Investors who already follow LungLife on the Investor Meet
Company platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards. A
recording of the presentation and a PDF of the slides used will
also be available on the LungLife website:
https://investors.lunglifeai.com/media/
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Daniel Adams / Virginia Bull / Cameron
MacRitchie
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 /
Marriage 07867 984 082
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSSAFAAEESEIU
(END) Dow Jones Newswires
September 09, 2022 02:01 ET (06:01 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024